The French Competition Authority rejects request for interim measures in pharmaceutical sector (Ratiopharm, Janssen-Cilag France)

In a decision of 31 July 2009, which was made public on 7 September 2009, the French Competition Authority rejected German generic pharmaceutical company Ratiopharm‘s request for interim measures against Janssen-Cilag France (“Janssen”), the maker of Durogesic. The move follows a complaint lodged by Ratiopharm alleging that Janssen had abused its dominant position by various practices aimed at slowing down the market entry of Ratiopharm‘s generic form of Durogesic, known as fentanyl. Fentanyl is a non-morphine opioid analgesic delivered, inter alia, in a transdermal patch. The French Competition

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
  • Practising Law Institute (New York)

Quotation

Tim Kasten, Sean Gerlich, The French Competition Authority rejects request for interim measures in pharmaceutical sector (Ratiopharm, Janssen-Cilag France), 31 July 2009, e-Competitions Bulletin Pharma & Dominance, Art. N° 41735

Visites 153

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues